The development of hypertension vaccine toward clinical application.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461127
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Cardiovascular medicine
• Research Institution: Osaka University
• Principal Investigator: Katsuya Tomohiro 大阪大学, 医学(系)研究科(研究院), 特任准教授 (30311757)
• Co-Investigator(Kenkyū-buntansha): NAKAGAMI Hironori 大阪大学, 大学院医学系研究科, 寄附講座教授 (20325369)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 高血圧症 / ワクチン / レニン / アンジオテンシンII

Outline of Final Research Achievements

To develop a novel therapy for hypertension, we evaluate the effectivity of vaccines against renin-angiotensin system. Angiotensin II DNA vaccine reduced perivascular fibrosis of heart tissue in spontaneously hypertensive rat (SHR). Then we construct renin epitope DNA vaccine. Anti-renin antibody was produced by administration of renin vaccine in SHR. Systolic blood pressure was significantly reduced in the renin vaccine group. Histological analysis revealed that there are no any pathological findings in the kidney, liver, and heart. These results indicate that small epitope vaccine targeting renin is safe and effective.

Free Research Field

老年・高血圧内科学